These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38218631)

  • 1. Corrigendum to "Anti-hypertrophy effect of atorvastatin on myocardium depends on AMPK activation-induced miR-143-3p suppression via Foxo1" [Biomed. Pharmacother. 106 (2018) 1390-1395].
    Yu B; Liu D; Zhang H; Xie D; Nie W; Shi K; Yang P
    Biomed Pharmacother; 2024 Feb; 171():116141. PubMed ID: 38218631
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-hypertrophy effect of atorvastatin on myocardium depends on AMPK activation-induced miR-143-3p suppression via Foxo1.
    Yu B; Liu D; Zhang H; Xie D; Nie W; Shi K; Yang P
    Biomed Pharmacother; 2018 Oct; 106():1390-1395. PubMed ID: 30119211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin attenuates cardiac hypertrophy through AMPK/miR-143-3p/Bcl2 axis.
    Sun J; Zhang C; Zhang Z
    Arch Physiol Biochem; 2021 Oct; 127(5):390-396. PubMed ID: 31353965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gypenoside A protects ischemia/reperfusion injuries by suppressing miR-143-3p level via the activation of AMPK/Foxo1 pathway.
    Chang L; Shi R; Wang X; Bao Y
    Biofactors; 2020 May; 46(3):432-440. PubMed ID: 31889343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of miR-143-3p contributes to the anti-fibrosis effect of atorvastatin on myocardial tissues via the modulation of Smad2 activity.
    Yu B; Yu M; Zhang H; Xie D; Nie W; Shi K
    Exp Mol Pathol; 2020 Feb; 112():104346. PubMed ID: 31758917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum to "MiR-25-3p promotes malignant phenotypes of retinoblastoma by regulating PTEN/Akt pathway" [Biomed. Pharmacother. 118 (2019) 109111].
    Wan W; Wan W; Long Y; Li Q; Jin X; Wan G; Zhang F; Lv Y; Zheng G; Li Z; Zhu Y
    Biomed Pharmacother; 2020 Nov; 131():110842. PubMed ID: 33092949
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC" [Biomed. Pharmacother. 110 (2019) 656-666].
    Quan J; Pan X; Li Y; Hu Y; Tao L; Li Z; Zhao L; Wang J; Li H; Lai Y; Zhou L; Lin C; Gui Y; Ye J; Zhang F; Lai Y
    Biomed Pharmacother; 2019 Apr; 112():108755. PubMed ID: 30871752
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "MiR-337-3p promotes chondrocytes proliferation and inhibits apoptosis by regulating PTEN/AKT axis in osteoarthritis" [Biomed. Pharmacother. 95 (2017) 1194-1200].
    Huang Z; Zhang N; Ma W; Dai X; Liu J
    Biomed Pharmacother; 2022 Sep; 153():113497. PubMed ID: 35948468
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "LINC00657 played oncogenic roles in esophageal squamous cell carcinoma by targeting miR-615-3p and JunB" [Biomed. Pharmacother. 108 (2018) 316-324].
    Yuchen S; Jizhao W; Shupei P; Tian Y; Xuanzi S; Ya W; Xiaobo S; Xu Z; Jing G; Xiaozhi Z
    Biomed Pharmacother; 2019 Mar; 111():1507. PubMed ID: 30600121
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Folate inhibits miR-27a-3p expression during cervical carcinoma progression and oncogenic activity in human cervical cancer cells" [Biomed. Pharmacother. 122 (2020) 109654].
    Wang Z; Wang W; Zhao W; Wang Z; Yang J; Wang W; Teng P; Su X; Li D; Zhang X; Wang H; Hao M
    Biomed Pharmacother; 2020 May; 125():109981. PubMed ID: 32067843
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Dexmedetomidine protects H9C2 against hypoxia/reoxygenation injury through miR-208b-3p/Med13/Wnt signaling pathway axis" [Biomed. Pharmacother. 125 (2020) 110001].
    Wang Z; Yang Y; Xiong W; Zhou R; Song N; Liu L; Qian J
    Biomed Pharmacother; 2020 Oct; 130():110841. PubMed ID: 33032881
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "LINC01116 targets miR-520a-3p and affects IL6R to promote the proliferation and migration of osteosarcoma cells through the Jak-stat signaling pathway" [Biomed. Pharmacother. 107 (2018) 270-282].
    Zhang B; Yu L; Han N; Hu Z; Wang S; Ding L; Jiang J
    Biomed Pharmacother; 2021 Jan; 133():110893. PubMed ID: 33280928
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "LINC01116 targets miR-520a-3p and affects IL6R to promote the proliferation and migration of osteosarcoma cells through the Jak-stat signaling pathway" [Biomed. Pharmacother. 107 (2018) 270-282].
    Zhang B; Yu L; Han N; Hu Z; Wang S; Ding L; Jiang J
    Biomed Pharmacother; 2019 Mar; 111():1508. PubMed ID: 30600120
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Saikosaponin A inhibits the activation of pancreatic stellate cells by suppressing autophagy and the NLRP3 inflammasome via the AMPK/mTOR pathway" [Biomed. Pharmacother. 128 (2020) 110216].
    Cui L; Li C; Zhuo Y; Yang L; Cui N; Li Y; Zhang S
    Biomed Pharmacother; 2020 Oct; 130():110685. PubMed ID: 32893050
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Protective effect of dioscin against thioacetamide-induced acute liver injury via FXR/AMPK signaling pathway in vivo" [Biomed. Pharmacother. 97 (2018) 481-488].
    Zheng L; Yin L; Xu L; Qi Y; Li H; Youwei X; Han X; Liu K; Peng J
    Biomed Pharmacother; 2019 Dec; 120():109448. PubMed ID: 31615697
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Cerebral dopamine neurotrophic factor protects microglia by combining with AKT and by regulating FoxO1/mTOR signaling during neuroinflammation" [Biomed. Pharmacother. 109 (2018) 2278-2284].
    Zhang Y; Xiang Y; Wang X; Zhu L; Li H; Wang S; Pan X; Zhao H
    Biomed Pharmacother; 2019 Apr; 112():108548. PubMed ID: 30773235
    [No Abstract]   [Full Text] [Related]  

  • 17. MiR-142-3p functions as an oncogene in prostate cancer by targeting FOXO1.
    Tan YF; Chen ZY; Wang L; Wang M; Liu XH
    J Cancer; 2020; 11(6):1614-1624. PubMed ID: 32047567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCε Pathway.
    Ren J; Liu W; Li GC; Jin M; You ZX; Liu HG; Hu Y
    Curr Med Sci; 2018 Jun; 38(3):405-412. PubMed ID: 30074205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum to "miR-152 regulated glioma cell proliferation and apoptosis via Runx2 mediated by DNMT1" [Biomed. Pharmacother. 92 (2017) 690-695].
    Zhang P; Sun H; Yang B; Luo W; Liu Z; Wang J; Zuo Y
    Biomed Pharmacother; 2020 Jun; 126():110090. PubMed ID: 32201084
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of microRNA-143-3p attenuates myocardial hypertrophy by inhibiting inflammatory response.
    Yu B; Zhao Y; Zhang H; Xie D; Nie W; Shi K
    Cell Biol Int; 2018 Nov; 42(11):1584-1593. PubMed ID: 30203887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.